Cabozantinib for Neuroendocrine Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
High grade neuroendocrine neoplasm patients are treated with platinum doublets such as carboplatin and etoposide mimicking the current guidelines for small cell lung cancer (SCLC). Unfortunately, recurrences are common and most patients with metastatic disease succumb to it within a year. There is no extensive literature or consensus on second- or third-line options (which include FOLFOX, FOLFIRI, capecitabine and temozolomide, taxanes or immunotherapy) and there is urgent need for better regimens.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you cannot take certain blood thinners like warfarin, and you must not have taken any small molecule kinase inhibitors or other systemic anticancer therapies within a few weeks before starting the trial.
Is cabozantinib safe for humans?
How is the drug Cabozantinib unique in treating neuroendocrine cancer?
What data supports the effectiveness of the drug Cabozantinib for neuroendocrine cancer?
Research shows that Cabozantinib can effectively reduce tumor growth and spread in neuroendocrine tumors by blocking certain proteins that help tumors grow and form new blood vessels. Studies in lab models and animals have shown promising results, suggesting it could be a useful treatment for these types of cancers.23478
Who Is on the Research Team?
Nikolaos Trikalinos
Principal Investigator
Washington University School of Medicine
Are You a Good Fit for This Trial?
Adults with high-grade neuroendocrine tumors that have worsened after first-line therapy can join this trial. They must not have small cell lung cancer, be in good physical condition, and agree to use contraception. Pregnant or breastfeeding women, those who've had cabozantinib before, recent major surgery or other cancer treatments are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Cabozantinib 60 mg by mouth daily on days 1-21
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cabozantinib
Cabozantinib is already approved in European Union, United States, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
Exelixis
Industry Sponsor
Michael M. Morrissey
Exelixis
Chief Executive Officer since 2010
PhD in Chemistry from Harvard University, BSc in Chemistry from the University of Wisconsin
Vicki L. Goodman
Exelixis
Chief Medical Officer since 2022
MD